Rosmarinic acid alleviates diabetic osteoporosis by suppressing the activation of NLRP3 inflammasome in rats
Physiology International · 10.03.2022 · 109 (1) · 46-57
DOI: 10.1556/2060.2022.00154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiology International, erschienen am 10.03.2022. Verfasst von Qingsong Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Second People's Hospital of Anhui Province, Hefei, 230041, Anhui, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Key Projects of Natural Science Research in Colleges and Universities of Anhui Province.
Abstract (Originalsprache)
Background
Diabetic osteoporosis is a common metabolic bone disorder characterized by bone loss in diabetic patients, which causes an enormous social burden due to the unsatisfactory outcome of current therapeutic strategy.
Methods
Based on the importance of inflammasome activation in diabetic osteoporosis, we evaluated the protective effect of an antioxidant, rosmarinic acid (RA) in diabetic osteoporosis. Bone marrow-derived monocytes isolated from rats were treated with receptor activator of nuclear factor kappa-Β ligand (RANKL) and macrophage colony stimulating factor to differentiate into mature osteoclasts (OCs). Next OCs were stimulated with RA under high glucose condition to evaluate bone resorption. Next, streptozotocin (STZ)-injected rats were orally treated with 50 mg kg −1 RA to analyze its effect on diabetic osteoporosis.
Results
RA inhibited high glucose-stimulated inflammation and inflammasome activation in OCs. Bone resorption was also reduced after RA treatment as shown by the resorption pits assay. Moreover, RA significantly reduced bone resorption, alleviated bone weight loss and increased bone mineral density by inhibiting the activation of NACHT-LRR-PYD domains–containing protein 3 (NLRP3) inflammasome in STZ-induced diabetic rats, leading to the improvement of diabetic osteoporosis.
Conclusion
RA effectively ameliorates diabetic osteoporosis in STZ-induced rats by inhibiting the activation of NLRP3 inflammasome in OCs, which suggests that RA might serve as a potential candidate drug for treating diabetic osteoporosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, Second People's Hospital of Anhui Province, Hefei, 230041, Anhui, China.
Förderung
- Key Projects of Natural Science Research in Colleges and Universities of Anhui Province
Zitieren
APA
Li, Q., Tao, X., & Zhang, Y. (2022). Rosmarinic acid alleviates diabetic osteoporosis by suppressing the activation of NLRP3 inflammasome in rats. Physiology International, 109(1), 46-57. https://doi.org/10.1556/2060.2022.00154
Vancouver
Li Q, Tao X, Zhang Y. Rosmarinic acid alleviates diabetic osteoporosis by suppressing the activation of NLRP3 inflammasome in rats. Physiology International. 2022;109(1):46-57. doi:10.1556/2060.2022.00154
BibTeX
@article{Li2022,
author = {Li, Qingsong and Tao, Xueshun and Zhang, Yubing},
title = {Rosmarinic acid alleviates diabetic osteoporosis by suppressing the activation of NLRP3 inflammasome in rats},
journal = {Physiology International},
year = {2022},
volume = {109},
number = {1},
pages = {46--57},
doi = {10.1556/2060.2022.00154}
}
EUVIMED